Wire · opportunities
ZYME: FDA approval, robust pipeline, and strategic partnerships drive growth and shareholder value
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
Zymeworks has secured FDA approval for zanidatamab to treat HER2-positive gastric cancer, unlocking new royalty and milestone revenues. The company is advancing multiple phase III trials and novel therapies, supported by strategic partnerships like the Theravance acquisition to drive sustained growth.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 14 Sep 2026 and 15 Sep 2026.
◆ ◆ The Wire takeaway
FDA approval opens direct US market access and revenue for your oncology drug development. Secure or deepen partnerships now to capitalise on long-term growth unlocked by regulatory validation.
◆ Coverage
1 source · first reported 14 Sep 2026 · latest 15 Sep 2026
◆ Related on Wire
◆ Topics